Promoting integrated care in prostate cancer through online prostate cancer-specific holistic needs assessment: a feasibility study in primary care.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 05 03 2019
accepted: 26 06 2019
pubmed: 25 7 2019
medline: 2 6 2020
entrez: 25 7 2019
Statut: ppublish

Résumé

This study assessed the feasibility of implementing a novel model of integrated prostate cancer care involving an online prostate cancer-specific holistic needs assessment (sHNA) and shared digital communication between patients and their healthcare professionals (HCPs). The sHNA produces a semi-automated care plan that is finalised in consultation between the patient and their practice nurse. Men living with and beyond prostate cancer were invited to participate in a 9-month non-randomised cluster controlled feasibility study. The intervention group was asked to complete the sHNA on three occasions. Data were collected using Patient Reported Outcome Measures (PROMs) at baseline, 10 and 24 weeks, and 9 months. Outcomes included recruitment, retention, acceptability, and engagement with the sHNA and PROMs. Fourteen general practices (8 intervention and 6 control), and 41 men (29 intervention and 12 control) participated. Initial patient engagement with the sHNA was high, with all but one receiving practice nurse-led follow-up and an individualised care plan. The sHNA proved useful in identifying 'red flag' symptoms, and helping practice nurses decide when to seek further medical care for the patients. There was a high level of acceptability for patients and HCPs. However, integration of care did not occur as intended because of problems linking hospital and general practice IT systems. While the study demonstrated the feasibility of implementing the sHNA, it did not meet the a priori progression criteria; as such, undertaking a definitive randomised controlled trial is not appropriate until the identified methodological and technical issues have been addressed.

Identifiants

pubmed: 31338642
doi: 10.1007/s00520-019-04967-y
pii: 10.1007/s00520-019-04967-y
pmc: PMC7036062
doi:

Types de publication

Controlled Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1817-1827

Subventions

Organisme : Research for Patient Benefit Programme
ID : PB-PG -0214-33092

Références

JCO Clin Cancer Inform. 2018 Dec;2:1-9
pubmed: 30652580
J Grad Med Educ. 2013 Sep;5(3):353-6
pubmed: 24404294
Am J Mens Health. 2018 Nov;12(6):1864-1872
pubmed: 29957106
Acta Oncol. 2013 Feb;52(2):391-9
pubmed: 23244672
BJU Int. 2016 Jun;117(6B):E10-9
pubmed: 25818406
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
JMIR Res Protoc. 2017 Jul 28;6(7):e147
pubmed: 28754653
Eur J Cancer Care (Engl). 2017 Jul;26(4):
pubmed: 28426142
Am J Prev Med. 2009 May;36(5):452-7
pubmed: 19362699
Br J Gen Pract. 2019 Jan;69(678):e70-e79
pubmed: 30510099
Cancer. 2008 Jan 15;112(2):228-42
pubmed: 18008363
Psychooncology. 2018 Oct;27(10):2339-2348
pubmed: 30255558
Health Expect. 2017 Oct;20(5):1081-1087
pubmed: 28467626
J Clin Epidemiol. 1997 Apr;50(4):441-50
pubmed: 9179103
J Clin Oncol. 2017 Jun 20;35(18):1978-1981
pubmed: 28437163
Psychooncology. 2018 Jan;27(1):22-33
pubmed: 29044832
J Clin Oncol. 2014 Jan 1;32(1):12-8
pubmed: 24276777
Am J Prev Med. 2016 Nov;51(5):843-851
pubmed: 27745684
Psychooncology. 2007 Sep;16(9):796-804
pubmed: 17177268
Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26
pubmed: 15230939
Eur J Cancer Care (Engl). 2017 May;26(3):
pubmed: 28497470
Health Qual Life Outcomes. 2007 Nov 27;5:63
pubmed: 18042300
Eur J Oncol Nurs. 2018 Feb;32:73-81
pubmed: 29353635
BMC Health Serv Res. 2019 Feb 12;19(1):115
pubmed: 30755188
J Patient Exp. 2017 Sep;4(3):114-120
pubmed: 28959716

Auteurs

Amy L Clarke (AL)

University of Warwick, Coventry, UK.

Julia Roscoe (J)

University of Warwick, Coventry, UK.

Rebecca Appleton (R)

University of Warwick, Coventry, UK.

Deepak Parashar (D)

Statistics and Epidemiology Unit, Warwick Medical School, University of Warwick, Coventry, UK.
The Alan Turing Institute, London, UK.
Warwick Cancer Research Centre, University of Warwick, Coventry, UK.

Radha Muthuswamy (R)

Prostate Cancer UK Information Technology Consultant, London, UK.

Omar Khan (O)

University of Warwick, Coventry, UK.

Jeremy Dale (J)

University of Warwick, Coventry, UK.

Veronica Nanton (V)

University of Warwick, Coventry, UK. V.nanton@warwick.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH